Trade Summary

1 week ago, McKechnie Duncan, serving as EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 1,541 shares at $519.00 per share, for a total transaction value of $799,779.00. Following this transaction, McKechnie Duncan now holds 11,001 shares of VRTX.

This sale represents a 12.29% decrease in McKechnie Duncan's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, July 2, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, July 7, 2026 at 4:08 PM ET, 5 days after the trade was made.

VERTEX PHARMACEUTICALS INC / MA operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.